IP Library Granted Patent US 10,220,092
Granted Patent B2
US 10,220,092 · App. 14/782,201 · Granted Mar 5, 2019

Devices, systems and methods for optogenetic modulation of action potentials in target cells

Inventors: Karl A. Deisseroth (Palo Alto, CA); Emily Anne Ferenczi (Stanford, CA); Peter Hegemann (Falkensee, DE)
Assignees: The Board of Trustees of The Leland Stanford Junior University; HUMBOLDT-UNIVERSITAT ZU BERLIN
A61K41/0057A01K67/0275A61N5/0613C07K14/00C07K14/705C12N15/85A01K2207/05A01K2227/105A01K2267/0393A61N2005/0662C07K2319/33C12N2750/14143C12N2830/002C12N2830/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,092
App. No.
14/782,201
Granted
Mar 5, 2019
Kind
B2
Abstract

Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells. The subject systems include light-activated proteins, response proteins, nucleic acids comprising nucleotide sequences encoding these proteins, as well as expression systems that facilitate expression of these proteins in target cells. Also provided are methods of using the subject devices and systems to optogenetically inhibit and intercept action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or non-human animal subject.

Claims (20)

1. A method for modulating the membrane potential of a mammalian cell in response to light, the method comprising exposing the cell to the light, wherein the cell is genetically modified with a nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide comprising:

a) a light-activated proton pump protein comprising an amino acid sequence having at least 90% homology to one of the amino acid sequences of SEQ ID NOs: 1, 4, 5, and 6; and

b) an acid-sensitive ion channel, wherein the acid-sensitive ion channel comprises an amino acid sequence having at least 80% homology to the ASIC2a polypeptide amino acid sequence of SEQ ID NO: 19, wherein the nucleotide sequence is operably linked to a promoter, and wherein exposure of the cell to the light activates the light-activated proton pump protein, wherein activation of the light-activated proton pump protein activates the acid-sensitive ion channel and thereby modulates the membrane potential of the cell.

2. The method of claim 1 , wherein the acid-sensitive ion channel amino acid sequence has at least 90% homology to the amino acid sequence of SEQ ID NO: 19.

3. The method of claim 1 , wherein the light-activated proton pump protein amino acid sequence has at least 95% homology to the amino acid sequence of any one of SEQ ID NOs: 1, 4, 5, and 6 , 16, and 62.

4. The method of claim 1 , wherein the fusion polypeptide comprises a membrane trafficking signal.

5. The method of claim 4 , wherein the membrane trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:37).

6. The method of claim 1 , wherein the promoter is a neuron-specific promoter.

7. The method of claim 1 , wherein the cell is a neuron.

8. The method of claim 1 , wherein the fusion polypeptide comprises an endoplasmic reticulum (ER) export signal.

9. The method of claim 8 , wherein the ER export signal comprises the amino acid sequence FCYENEV (SEQ ID NO:47).

10. The method of claim 1 , wherein the light-activated proton pump protein amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:1.

11. The method of claim 1 , wherein the light-activated proton pump protein amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:4.

12. The method of claim 1 , wherein the light-activated proton pump protein amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:5.

13. The method of claim 1 , wherein the light-activated proton pump protein amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:6.

14. The method of claim 1 , wherein the acid-sensitive ion channel amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:19.

15. The method of claim 1 , wherein the fusion polypeptide amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:31.

16. The method of claim 1 , wherein the fusion polypeptide amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:32.

17. The method of claim 1 , wherein the fusion polypeptide amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:33.

18. The method of claim 1 , wherein the fusion polypeptide amino acid sequence has at least 95% homology to the amino acid sequence of SEQ ID NO:34.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2021
From: HOWARD HUGHES MEDICAL INSTITUTE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 055604/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2021
From: FERENCZI, EMILY ANNE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 055605/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2021
From: DEISSEROTH, KARL
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 055605/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2015
From: HEGEMANN, PETER
To: HUMBOLDT-UNIVERSITÄT ZU BERLIN
Reel/Frame 036760/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2015
From: DEISSEROTH, KARL A.; FERENCZI, EMILY ANNE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 036760/0507 →
Continuity (2)
Provisional Application 61817221 · Apr 29, 2013
Related Publication 20160045599A1 · Feb 18, 2016
Cited By (3)
US 12,510,744 US 12,655,474 US 12,730,295